Albers, LJ, Reist, C, Helmeste, D et al (1996) Paroxetine shifts imipramine metabolism. Psychiatry Research; 59: 189–96.
Alvan, G, Bechtel, P, Iselius, L et al (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. European Journal of Clinical Pharmacology; 39: 533–7.
Bitsios, P, Szabadi, E, Bradshaw, CM (1999) Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology; 143: 286–92.
Blier, P (2008) Resiliency of monoaminergic systems: the 80% rule and its relevance to drug development. Journal of Psychopharmacology; 22: 587–9.
Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology; 25: 871–80.
Daws, LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacology and Therapeutics; 121: 89–99.
Debonnel, G, Saint-André, É, Hébert, C et al (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology; 10: 51–61.
Dodd, S, Horgan, D, Malhi, GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders; 89: 1–11.
Fava, M, Rosenbaum, JF, McGrath, PJ et al (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry; 151: 1372–4.
Fava, M, Alpert, J, Nierenberg, A et al (2002) Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. Journal of Clinical Psychopharmacology; 22: 379–87.
Harvey, AT, Rudolph, RL, Preskorn, SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry; 57: 503–9.
Ingelman-Sundberg, M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal; 5: 6–13.
Meyer, JH, Wilson, AA, Sagrati, S et al (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. American Journal of Psychiatry; 161: 826–35.
Nelson, JC, Mazure, CM, Bowers, MB et al (1991) A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry; 48: 303–7.
Nelson, JC, Mazure, CM, Jatlow, PI et al (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry; 55: 296–300.
Owens, MJ, Krulewicz, S, Simon, JS et al (2008) Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology; 33: 3201–12.
Papakostas, G, Fava, M, Thase, M (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological Psychiatry; 63: 699–704.
Vaishnavi, SN, Nemeroff, CB, Plott, SJ et al (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry; 55: 320–2.